Publications 2006

1 The Use of the Framingham Equation to Predict Myocardial Infarctions in HIV-infected Patients: Comparison with Observed Events in the D:A:D Study.
MG Law, N Friis-Møller, WM El-Sadr, R Weber, P Reiss, A D'Arminio Monforte, R Thiébaut, L Morfeldt, S De Wit, C Pradier, G Calvo, O Kirk, CA Sabin, AN Phillips, and JD Lundgren for the D:A:D Study Group.
HIV Med. 2006;7;218-230 abstract

2 Relationship between antiretrovirals used as part of a cART regimen and CD4 count increases in patients with suppressed viremia. A Mocroft,  A Phillips, B Ledergerber, C Katlama, A Chiesi F Goebel, B Knysz, F Antunes, P Reiss, J Lundgren for the EuroSIDA study group.
AIDS. 2006 May 12;20(8):1141-1150 abstract 

3 The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. A Mocroft, J Neaton, J Bebchuk, S Staszewski, F Antunes, B Knysz, M Law, AN Phillips, J Lundgren for the EuroSIDA and ESPRIT study groups.
Clin Trials. 2006 May;3(2):119-132 abstract

4  Regional changes over time in initial virological response rates to combination antiretroviral therapy across Europe. W Bannister, O Kirk, J Gatell, B Knysz, J-P Viard, H Mens, A D'Arminio Monforte, A Phillips, A Mocroft, J Lundgren for the EuroSIDA study group. 
J Acquir Immune Defic Syndr. 2006 Jun;42(2):229-237 abstract

5 Liver-related deaths among persons infected with the human immunodeficiency virus: The D:A:D Study. Writing committee: R Weber, CA Sabin, N Friis-Møller, P Reiss, WM. El-Sadr, O Kirk, F Dabis, MG Law, C Pradier, S De Wit, B Åkerlund, G Calvo, A d’Arminio Monforte, M Rickenbach, B Ledergerber, AN Phillips, and JD Lundgren
Arch Intern Med. 2006;166:1632-1641 abstract

6 Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Writing committee: P Yeni, DA Cooper, J-P Aboulker, AG Babiker D Carey, JH Darbyshire, M Floridia, P-M Girard, RL Goodall, MH Hooker, A Mijch, V Meiffredy, B Salzberger for the INITIO trial coordinating committee.
Lancet. 2006; 368:287-98 abstract

7 Factors associated with development of opportunistic infections in HIV-1 infected adults with high CD4 cell counts: a EuroSIDA study. D Podlekareva, A Mocroft, UB Dragsted, B Ledergerber, M Beniowski, A Lazzarin, J Weber, N Clumeck, N Vetter, A Phillips, and JD Lundgren for the EuroSIDA study group
J Infect Dis. 2006 Sep 1; 194(5):633-41 abstract

8 Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. M Puoti, A Cozzi-Lepri, C Arici C, NF Moller, JD Lundgren, B Ledergerber, M Rickenbach, I Suarez-Lozano, M Garrido, F Dabis, M Winnock, L Milazzo, A Gervais, F Raffi, J Gill, J Rockstroh, N Ourishi, C Mussini, A Castagna, A De Luca, A Monforte; HBV-HIV International Intercohort Study Group. 
Antivir Ther. 2006;11(5):567-74 abstract

9 Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials. A Lifson, FS Rahme, WH Belloso, UB Dragsted, WM El-Sadr, JM Gatell, JF Hoy, EA Krum, R Nelson, C Pedersen, SL Pett, RT Davey for the ESPRIT and SILCAAT Research Groups.
HIV Clin Trials. 2006;7(3):125-141 abstract

10 HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. M May, J Sterne, D Costagliola, M Egger, C Sabin, A Phillips, A Justice, F Dabis, J Gill, J Lundgren, R Hogg, F de Wolf, G Fätkenheuer, S Staszewski, and A d´Arminio Monforte for  The Antiretroviral Therapy (ART) Cohort Collaboration.
Lancet. 2006 Aug 5;368(9534):451-8 abstract

11 HIV-1 subtypes and response to combination antiretroviral therapy in Europe. WP Bannister, L Ruiz, C Loveday, S Vella, K Zilmer, J Kjær, B Knysz, AN Phillips, A Mocroft, JD Lundgren for the EuroSIDA study group
Antiviral Therapy 2006; 11: 707-715 abstact

12 A randomized trial to evaluate continuation versus discontinuation fo lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. Z Fox, UB Dragsted, J Gerstoft, AN Phillips, J Kjaer, L Mathiesen, M Youle, C Katlama, A Hill, JN Bruun, N Clumeck, P Dellamonica and JD Lundgren on behalf of the The COLATE study group
Antiviral Therapy 2006; 11: 761-770 abstract

13 CD4+ Count-Guided Interruption of Antiretroviral Treatment. The Strategies for Mangement of Antiretroviral Therapy (SMART) Study Group. Writing Group: WM El-Sadr, JD Lundgren, JD Neaton, F Gordin, D Abrams, RC Arduino, A Babiker, W Burman, N Clumeck, CJ Cohen, D Cohn, D Cooper, S Emery, G Fätkenheuer, B Gazzard, B Grund, J Hoy, K Klingman, M Losso, N Markowitz, J Neuhaus, AN Phillips, and C Rappoport.
N Engl J Med 2006; 355(22); 2283-2296 abstract 

14 The impact of antiretroviral therapy on AIDS and survival. JD Lundgren, A Mocroft
J HIV Ther.2006 Jun;11(2):36-8 abstract article

15 Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. A Mocroft, J Rockstroh, V Soriano, O Kirk, J-P Viard, S Caplinskas, J Gasiorowski, A Chiesi, AN Phillips, JD Lundgren for the EuroSIDA Study.
Scand J Inf Dis. 2006;38:1092-1097 abstract

16 Hearing loss and cochlear damage in experimental pneumococcal meningitis, with special reference to the role of neutrophil granulytes. CT Brandt, P Caye-Thomsen, SP Lund, L Worsøe, C Østergaard, N Frimodt-Møller, F Espersen, J Thomsen, JD Lundgren.
Neurobiol Dis. 2006 Aug;23(2):300-11 abstract

17 Evaluation of anti-pneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis. CT Brandt, N Frimodt-Moller, JD Lundgren, M Pedersen, IC Skovsted, IJ Rowland, C Ostergaard.
J Antimicrob Chemother. 2006 Dec;58(6):1291-4 abstract

18 Influence of the blood bacterial load on the meningeal inflammatory response in Streptococcus pneumoniae meningitis. C Ostergaard, T O'Reilly, C Brandt, N Frimodt-Moller, JD Lundgren. 
BMC Infect Dis. 2006 Apr 27;6:78 abstract

19 Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000. A Mocroft, A Horban, N Clumeck, HJ Stellbrink, A d´Arminio Monforte, K Zilmer, O Kirk, J Gatell, AN Phillips, and JD Lundgren for the EuroSIDA study group.
HIV Clin Trials. 2006;7(6):271-284 abstract

20 The CD4 lymphocyte count and risk of clinical progression. AN Phillips and JD Lundgren
Curr. Opin. in HIV&AIDS. 2006 Jan; 1(1):43-49 abstract 

21 Procalcitonin increase in early identification of critically ill patients at high risk of mortality. JU Jensen, L Heslet, TH Jensen, K Espersen, P Steffensen, M Tvede.
Crit Care Med. 2006 Oct;34(10):2596-602 abstract

22 The ART Cohort Collaboration. Rates of disease progression according to initial HAART regimen: A collaborative analysis of 12 prospective cohort studies. Writing committee: Robert Hogg, Margaret May, Andrew Phillips, Dominique Costagliola, Jonathan Sterne, Caroline Sabin, Frank De Wolf, Bruno Ledergerber, Antonella D'Arminio Monforte, Amy Justice, John Gill, Gregory Fusco, Schlomo Staszewski, Jurgen Rockstroh, Geneviève Chêne and Matthias Egger. Journal of Infectious Diseases 2006 194: 612-622

23 Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and the ART Cohort Collaboration. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Braitstein P, Brinkhof MWG, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg D, Balestre E, Sterne J, May M, Egger M. Lancet 2006 367: 817-824.

Updated: 16 Sep 2009